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ABSTRACT
Objective Knee osteoarthritis (OA) is a heterogeneous, 
complex joint pathology of unknown aetiology. Biomarkers 
have been widely used to investigate OA but currently 
available biomarkers lack specifi city and sensitivity. 
Therefore, novel biomarkers are needed to better 
understand the pathophysiological processes of OA 
initiation and progression.
Methods Surface enhanced laser desorption/ionisation-
time of fl ight-mass spectrometry proteomic technique 
was used to analyse protein expression levels in 284 
serum samples from patients with knee OA classifi ed 
according to Kellgren and Lawrence (K&L) score (0–4). 
OA serum samples were also compared to serum 
samples provided by healthy individuals (negative 
control subjects; NC; n=36) and rheumatoid arthritis 
(RA) patients (n=25). Proteins that gave similar signal 
in all K&L groups of OA patients were ignored, whereas 
proteins with increased or decreased levels of expression 
were selected for further studies.
Results Two proteins were found to be expressed 
at higher levels in sera of OA patients at all four K&L 
scores compared to NC and RA, and were identifi ed as 
V65 vitronectin fragment and C3f peptide. Of the two 
remaining proteins, one showed increased expression 
(unknown protein at m/z of 3762) and the other (identifi ed 
as connective tissue-activating peptide III protein) was 
decreased in K&L scores >2 subsets compared to NC, 
RA and K&L scores 0 or 1 subsets.
Conclusion The authors detected four unexpected 
biomarkers (V65 vitronectin fragment, C3f peptide, 
CTAP-III and m/z 3762 protein) that could be relevant in 
the pathophysiological process of OA as having signifi cant 
correlation with parameters refl ecting local infl ammation 
and bone remodelling, as well as decrease in cartilage 
turnover.
INTRODUCTION
Osteoarthritis (OA) is one of the most common 
chronic joint diseases causing substantial health 
defi cits1 and it is becoming increasingly more prev-
alent as a result of population ageing. Obesity is 
a major risk factor for developing OA and recent 
data suggest that there will be an epidemic of obe-
sity-related OA in the general population.2 Current 
diagnosis of OA depends on patient-reported pain 
and disability and is confi rmed by plain radiogra-
phy of affected joints. The pathophysiology of OA 
is characterised by dysregulation of normal joint 
homeostasis that leads to intra-articular tissue deg-
radation, with attempted repair and infl ammation 
mediated by cytokines and growth factors. Serum 
levels of macromolecules (biomarkers) can provide 
a way of measuring these processes,3–8 whereas 
others are putative markers of radiographic dis-
ease outcome in knee OA or have some diagnostic 
value.9–12 However, these biomarkers (singly or in 
combination) often lack the specifi city and sensitiv-
ity to discriminate individual patients from control 
subjects or to suggest possible disease progression 
for patients over time. Therefore, there is an urgent 
need to seek novel and more specifi c-biomarkers 
for investigation of OA and other joint diseases.
To that end, new proteomics studies related to 
discovery of biomarkers specifi c to OA pathol-
ogy have been performed by two-dimensional 
electrophoresis or liquid chromatography-mass 
spectrometry on serum,13 14 synovial fl uid15 16 or 
cartilage and chondrocyte secretomes,1 17–21 and 
these studies were recently reviewed.22 23 In the 
present study, the surface enhanced laser desorp-
tion/ionisation-time of fl ight-mass spectrometry 
(SELDI-TOF-MS) proteomics approach was used 
to investigate large serum sample cohorts. SELDI-
TOF-MS is a powerful ProteinChip technology that 
differentially investigates levels of low molecular 
weight proteins (<20 kDa) in biological fl uids.24–28 
In this type of study, unusually high or low protein 
signals are the main interest and these are consid-
ered as potential biomarkers of the disease pro-
cess. SELDI ProteinChip includes chromatographic 
chemistry for capturing proteins according to their 
physicochemical properties and displaying various 
protein profi les from the same studied biological 
sample, thus considerably increasing chances of 
identifying specifi c biomarkers.
In the present study, serum samples from well-
characterised groups of OA patients, healthy con-
trol subjects and disease control subjects (patients 
with rheumatoid arthritis (RA)) were analysed 
using SELDI-TOF-MS to search for novel and spe-
cifi c biomarkers for OA.
PATIENTS AND METHODS
Patients
Two-hundred and eighty-four patients with knee 
OA recruited through community questionnaires, 
consultations and hospital outpatient clinics,10 11 
and classifi ed according to their Kellgren and 
Lawrence (K&L) score,29 were used for the study. 
Of the 284 OA patients, 130 were included in the 
serum analysis study from Bristol OA 500 cohort, 
which has been described fully in previous publi-
cations8 10 and been shown to be appropriate for 
biomarker studies. The 154 OA patients used in 
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corticosteroid injection or NSAID use. Nineteen paired serum/
synovial fl uid samples (12 OA and seven RA patients) were used 
for correlation between both fl uids.
The study protocol was approved by the institutional review 
boards (Research Ethics Committee) of the United Bristol 
Healthcare NHS trust, Bristol, UK, and the University Hospital, 
CHU Liège, Belgium.
Serum samples and synovial fl uids
Blood samples were allowed to coagulate in plain glass tubes. 
Serum was obtained by centrifugation at 2800 rpm for 10 min. 
Synovial fl uids were processed using the same experimental 
conditions. Supernatants were aliquoted and immediately fro-
zen at −80°C until required for SELDI-TOF-MS analysis.
ProteinChip array preparation and data preprocessing
The choice of ProteinChip arrays, subsets of samples and the 
overall strategy for the OA proteomic study is summarised in fi g-
ure 1. ProteinChip array preparation and data preprocessing are 
described in the supplementary data and in previous studies.32 33
Protein purifi cation for biomarkers identifi cation
The proteomic study detected four proteins at different m/z 
ratios as putative biomarkers and a range of biochemical meth-
ods were used to characterise and identify these markers as 
described in the supplementary data.
the Validation study are from a more recent Bristol cohort. The 
demographic, clinical and radiographic data of these patients 
have also been published9 11 12 and demonstrated to be a suit-
able cohort for biomarker studies. The demographic and epi-
demiologic data of these patients are summarised in table 1. 
None of the OA patients were on intra-articular steroids or any 
potential disease-modifying drugs, the majority were on analge-
sics or non-steroidal anti-infl ammatory drugs (NSAIDs) that are 
unlikely to affect serum or synovial fl uid levels of the markers 
investigated.
Twenty-fi ve RA patients fulfi lling the 1987 American College 
of Rheumatology criteria30 and 36 healthy individuals (referred 
to as negative control subjects (NC)) were included in the study 
as control subjects. Of the 25 RA patients, 84%, 80% and 71% 
presented an elevated erythrocyte sedimentation rate (>40 
mm/h), rheumatoid factor (>20 IU/ml) and anti-CCP2 antibody 
(>5 IU/ml) score respectively. The median disease activity score 
using 28 joint counts (DAS28) was 7 (range 5.5–8.4), with 100% 
of the scores >5.1 (high disease activity).31 The mean numbers 
of tender and swollen joints were 15 (range 6–28) and 12 (range 
6–27) respectively. Concomitant treatments included metho-
trexate at a mean dosage of 14.5 mg/week (range 7.5–20 mg/
week) in six (24%) of 25 patients, and prednisolone at a mean 
dosage of 2.7 mg/day in eight (32%) of 25 patients.
NC qualifi ed for entry into the proteomics study consider-
ing the following exclusion criteria: any prior history of knee 
trauma, joint pain, chronic infl ammatory or autoimmune disease, 
Table 1 Demographic and clinical characteristics of the patients and control subjects used in the study
OA (n=130)
 Analysis set (n=150) NC K&L0 K&L1 K&L2 K&L3 K&L4
 Number of patients 20 44 17 20 23 26
 Female (%) 60 75 71 70 65 35
 Age at entry 57.5 (47–63) 57 (34–79) 59 (51–71) 60.5 (50–81) 60 (30–83) 62.5 (51–78)
 Age at onset / 44 (25–74) 50 (16–67) 47 (23–66) 51 (17–68) 41.5 (13–75)
 Disease duration / 6 (1–44) 8 (1–44) 11 (1–49) 10 (1–42) 20 (3–64)
 Body mass index (kg/m2) 25 (19–31) 25 (19–40) 26 (18.5–39) 23.5 (19–34) 27 (21–37) 28 (22.5–45)
 Number of joints
 Early morning stiffness / 3 (0–180) 30 (0–120) 5 (0–120) 5 (0–360) 10 (0–120)
 % With elevated CRP (>6 mg/l) 5 10 8 16 18 5
Validation set (n=195) NC
OA (n=154)
RAK&L0 K&L1 K&L2 K&L3 K&L4
 Number of patients 16 24 22 32 61 15 25
 Female (%) 50 58 77 75 48 46 64
 Age at entry 56 (49–64) 61 (43–79) 60 (38–78) 64 (45–92) 68 (43–81) 68 (52–76) 55 (25–77)
 WOMAC pain / 6 (2–20) 7 (0–20) 8 (2–15) 7 (1–14) 11 (5–17) /
 WOMAC stiffness / 4 (0–8) 4 (1–6) 4 (1–7) 4 (0–6) 4 (2–7) /
 WOMAC function / 21 (2–68) 27 (0–45) 27 (6–53) 24 (1–49) 34 (18–44) /
 Body mass index (kg/m2) 23 (20–30) 28 (21–44) 31 (23–48) 29 (19–42) 28 (22–41) 31 (23–39) /
 % With elevated CRP (>6 mg/l) / 21 18 22 10 14 78
Paired serum and synovial fl uids 
(n=19) NC
OA (n=12)
RAK&L0 K&L1 K&L2 K&L3 K&L4
 Number of patients / / 2 3 3 4 7
 Female (%) / / 0 67 100 100 57
 Age at entry / / 70 (64–77) 67 (67–68) 69 (65–83) 77 (62–81) 58 (44–68)
 Age at onset / / 65 (62–68) 67 (62–67) 68 (60–79) 75 (61–77) 44 (24–58)
 disease duration / / 5 (1–10) 1 (0.5–1) 3.5 (1–5) 3 (1–24) 10 (1.5–20)
 Body mass index (kg/m2) / / 28 (24–33) 29 (24–35) 32 (28–34) 25 (25–36) /
 % With elevated CRP (>6 mg/l) / / 0 0 0 0 71
Except where indicated otherwise, values are the median (range).
CRP, C reactive protein; K&L, Kellgren and Lawrence score; NC, negative control subjects; OA, osteoarthritis; RA, rheumatoid arthritis; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis Index.
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(CM10) and nickel affi nity (IMAC-Ni) ProteinChip arrays. 
Biomarker Wizard software resolved 156 and 134 peaks on 
CM10 and IMAC-Ni respectively. Ranking of biomarkers in the 
top 13 is summarised in the Analysis section of table 2, and is 
made according to the Imp(%) given by the multivariate analy-
sis. A p value for each biomarker was also calculated.
Serum validation studies
A new proteomic study (Validation 1) was designed with an 
independent set of samples (see table 1 and fi gure 1) to con-
fi rm the robustness of biomarkers detected after analysis study. 
The same statistical approaches were used for peak ranking as 
employed for the Analysis set (table 2, Validation 1 section).
Comparison of the Analysis and Validation studies allowed 
detection of four potential novel biomarkers at 1979, 2021, 3762 
and 9292 m/z values (fi gure 2). Peak intensity distributions in 
the NC, OA (K&L0 to 4) and RA groups are shown in fi gure 
2A–D.
Peak intensities at 1979 and 2021 m/z values were found to 
be signifi cantly (p<0.001, table 3) increased in all OA samples 
compared to NC and RA samples, and further increased with 
increasing K&L scores (fi gure 2A,B).
Intensities at 3762 and 9292 m/z values were signifi cantly 
higher (m/z=3762) or lower (m/z=9292) (table 3) in OA patients 
than in control groups, and the former (fi gure 2C) increased 
with increasing K&L scores of OA patients whereas the lat-
ter (fi gure 2D) decreased with increasing K&L scores. Figure 
2E–G shows the four biomarkers in gel view spectra from 10 
OA patients with K&L0 and 10 with K&L4. The fi gure shows 
that the biomarkers with m/z values at 1979, 2021 and 3762 
are barely detectable in K&L0 but they are present at much 
higher concentrations in serum samples from patients with 
Correlation with currently available biomarker assays
In order to further characterise the four putative biomarkers, 
biomarker peak intensities were correlated at 1979, 2021, 3762 
and 9292 m/z values with 20 different biochemical markers 
associated with cartilage, bone and synovial tissue metabolism 
(supplementary table 1). These markers had been previously 
measured by ELISA-based assays9 in 93 of the 154 OA serum 
samples used in the Validation 1 set, and were equally distrib-
uted among the K&L scores.
Statistical analyses
SELDI proteomics data were analysed by two statistical 
approaches: a non-parametric Mann–Whitney U test and a 
machine-learning algorithm called Extra-Trees N. The latter 
approach is a decision-tree multivariate analysis used to build 
classifi cation models and to rank peaks according to their rela-
tive contribution, quantifi ed by a percentage of importance 
(Imp(%)), in the classifi cation of two groups.34 In this model, m/z 
peak values were ranked in relation to their Imp(%) for differ-
entiating K&L0 from K&L4 groups. First values represent poten-
tial biomarkers involved in the development of OA. p Values 
are associated to this ranking and are considered signifi cant if 
≤0.05. For determining the association with currently available 
biomarkers, ranked data were used to calculate Spearman cor-




From the 130 OA and 20 NC serum samples (Analysis set, table 1 
and fi gure 1), 300 spectra were obtained on cation exchange 
Table 2 The m/z values, high percentage of importance (Imp(%)) and corresponding p values of the proteins with concentrations that differed 
signifi cantly between K&L0 and K&L4 groups
CM10 Analysis Validation 1 Validation 2
IDm/z Imp(%) Rank p Value Rank Imp(%) Rank p Value Rank p Value Rank
3762 5.68 1 1.9×10−7 1 13.62 1 1.1×10−6 3 4.4×10−3 27 NI
2021 4.48 2 2.8×10−5 9 1.30 19 2.4×10−4 17 1.5×10−4 14 C3f
3364 3.98 3 1.4×10−6 2 NS NS NS NS NS NS NI
4530 3.96 4 2.1×10−5 7 NS NS NS NS NS NS CTAPIII variant* (2H+)
8862 3.80 5 2.0×10−6 4 NS NS NS NS NS NS β-TG
9292 3.46 6 3.3×10−5 10 NS NS 3.4×10−4 27 0.01 NS CTAPIII
9060 2.70 7 2.3×10−5 8 NS NS NS NS NS NS CTAPIII variant
11 238 2.68 8 1.8×10−3 22 NS NS NS NS NS NS NI
7766 2.59 9 3.7×10−5 11 NS NS NS NS NS NS PF4
4430 2.18 10 5.6×10−6 5 NS NS NS NS NS NS β-TG* (2H+)
3157 1.99 11 7.5×10−5 13 NS NS NS NS NS NS NI
4644 1.98 12 4.7×10−5 12 NS NS 3.8×10−2 64 NS NS CTAPIII* (2H+)
1979 1.21 13 1.7×10−3 21 2.27 8 3.8×10−6 6 1.0×10−3 23 V65 Vitronectin fragment
IMAC Analysis Validation 2
IDm/z Imp(%) Rank p Value Rank     p Value Rank
4286 5.64 1 3.9×10−4 3 NS NS NI
11 683 4.45 2 8.8×10−5 1 NS NS SAA
2021 4.22 3 3.2×10−4 4 2.0×10−6 11 C3f
1691 ND ND ND ND 1.6×10−7 6 C3f
1778 ND ND ND ND 2.2×10−7 8 C3f
1865 ND ND ND ND     1.2×10−6 9 C3f
Two statistical analyses, a machine-learning algorithm called Extra-Trees N (Imp%) and a non-parametric Mann–Whitney U test (p values), were used for ranking m/z values according 
to their relative contribution for differentiating K&L0 and K&L4 groups in the Analysis, Validation 1 and Validation 2 surface enhanced laser desorption/ionisation-time of fl ight-mass 
spectrometry studies. Ranking of m/z values by both approaches is mentioned in the ‘Rank’ section.
*Doubly charged form (2H+).
β-TG, β-thromboglobulin; CTAPIII, connective tissue-activating peptide III; ND, not detected due to the use of SPA matrix allowing peak detection only from 2000 m/z value; NI, not 
identifi ed; NS, not statistically signifi cant.
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m/z values on IMAC-Ni. These new biomarkers are illustrated 
in fi gure 2H–K and were found to be variants of the 2021 m/z 
peak as further discussed below. The 2021 m/z biomarker can 
also be visualised in gel view K&L4 spectra (IMAC-Ni arrays) 
(fi gure 2K).
Synovial fl uid analysis study
Peaks at 1979, 2021 and 3762 m/z values were simultaneously 
identifi ed in serum and synovial fl uid samples of OA patients at 
different K&L scores (fi gure 3). Peaks at 9292 m/z value were 
only detected in serum, not synovial fl uids, of all OA and RA 
K&L scores of 4, whereas the opposite is true for the biomarker 
at m/z value of 9292.
Validation 2 was performed in a single day with K&L0 (n=24) 
and K&L4 (n=15) patients from Validation 1, to ensure that these 
four biomarkers were not artefacts due to the time spent during 
the Validation 1 study performed over 6 days. It allowed for dis-
carding any technical ambiguities and strengthening the validity 
of the four biomarkers still showing p values below 0.05 (table 
2 – Validation 2). Moreover, using α-cyano-4-hydroxycinnamic 
acid (CHCA), which allows for better visualisation of small pep-
tides, new biomarkers were detected at 1691, 1778 and 1865 
Figure 1 Strategy – 150 serum samples used for analysis were loaded on CM10 and IMAC-Ni ProteinChip arrays. Statistical analysis revealed 
13 and three putative biomarkers on CM10 and IMAC-Ni respectively. Therefore, a fi rst validation study (Validation 1) was performed using an 
independent set of 195 serum samples. These samples were loaded on CM10 but not on IMAC-Ni arrays as only three putative biomarkers were 
previously detected using this kind of array. Four biomarkers were validated at m/z values of 1979, 2021, 3762 and 9292. A second validation study 
(Validation 2) was performed using a subset of 39 serum samples, including the K&L0 and K&L4 grades used for Validation 1. Validation 2 was 
performed on CM10 and IMAC-Ni arrays in a day to minimise variability across the time. CHCA instead of SPA matrix was used for IMAC arrays to 
better visualise small peptides below 2000 Da such as truncated variants of C3f (m/z=2021). Finally, paired serum and synovial fl uid samples from 
12 osteoarthritis (K&L1 to 4) and seven rheumatoid arthritis patients were loaded on CM10 and IMAC-Ni arrays, and analysed to check for the new 
biomarkers’ presence in both fl uids.
I. Analysis (6 days)
n=150; (20 NC + 130 OA)  
Statistical analysis
13 putative biomarkers 3 putative biomarkers
II. Validation 1 (6 days)
n=195; (16 NC + 154 OA + 25 RA)
III. Validation 2 (1 day)
n=39;  (24 K&L0 + 15 K&L4)
4 validated biomarkers 





1 validated biomarkers 
m/z= 1691; C3f (truncated form)
m/z= 1778; C3f (truncated form)
m/z= 1865; C3f (truncated form)
(+ 3 variants)
IV. Paired serum and synovial fluid analysis 
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end of CTAPIII and is better known as β-thromboglobulin 
(β-TG) protein.
Correlation with currently available biomarker assays
Peak intensities corresponding to 1979 (V65 vitronectin frag-
ment), 2021 (C3f), 3762 (unknown) and 9292 (CTAPIII) m/z 
values and detected in spectra generated by 93 OA serum sam-
ples, were correlated to a wide range of currently available bio-
markers (supplementary table 1). The V65 vitronectin fragment 
was positively correlated with C-telopeptide of type II collagen 
(CTXII) and negatively with aggrecan and pro-matrix metallo-
protein 1 (pro-MMP-1) (supplementary table 2). The C3f peptide 
was negatively correlated with aggrecan and pyridinoline (pyd). 
The protein fragment at 3762 m/z value showed positive corre-
lation with cartilage glycoprotein 39 (YKL-40), MMP-3, pyd and 
patients (fi gure 3). Finally, peaks corresponding to variants of the 
2021 m/z biomarker (m/z=1691 and 1778) were also detected in 
both fl uids.
Biomarkers identifi cation
Proteins at 1979, 2021 and 9292 m/z values were purifi ed 
using classical chromatography approaches and identifi ed as 
the C-terminal end product of the V65 vitronectin subunit, the 
C3f peptide and the connective tissue-activating peptide III 
(CTAPIII), respectively, as further described in the supplemen-
tary data. Peaks at 1691, 1778, 1865 and 2021 m/z values were 
found clustered on spectra provided by IMAC-Ni arrays, and 
therefore are variants (truncated form at the C-terminal end by 
3, 2 and 1 amino acid respectively) of C3f peptides. The 8862 
m/z value is a four amino acid truncated form at the N-terminal 
Figure 2 (A–D) Peak intensity distribution of serum biomarkers detected after Validation 1 study on CM10 (m/z=1979, 2021, 3762 and 9292) 
through the seven groups of patients (negative control subjects, K&L0 1, 2, 3, 4 and rheumatoid arthritis). (E–G) Gel view spectra provided by 20 
patients with osteoarthritis (OA) (10 with K&L0 and 10 with K&L4) representing 1979 and 2021, 3762 and 9292 m/z markers respectively. (H–J) 
Variants (m/z=1691, 1778 and 1865) from m/z 2021 on IMAC-Ni through K&L0 and K&L4 groups after Validation 2 on serum. (K) Gel view spectra 
provided by 20 patients with OA (10 with K&L0 and 10 with K&L4) representing 1691, 1778, 1865 and 2021 m/z markers after Validation 2 on serum.
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both fl uids. Accordingly, the serum V65 vitronectin fragment 
may be derived from joint fl uid/tissues and appeared to be an 
interesting marker of OA. Clearly, further studies are required 
to confi rm its diagnostic value.
Vitronectin is a cell adhesion and spreading factor found in 
serum and in many tissues including cartilage and synovium.35 It 
is recognised by αVβ3 integrin receptor. Interaction of vitronec-
tin through its RGD motif36 has been well described.37–39 Highly 
expressed αVβ3 integrins have been detected on bone-resorbing 
osteoclasts and were shown to play an essential role in mediat-
ing osteoclast attachment to bone matrix allowing active bone 
resorption.37 40 41 A weak expression of αVβ3 integrin receptor 
has also been observed on chondrocytes,42 and this has been 
described as a major player in the regulation of infl ammatory 
mediators (interleukin 1β, nitric oxide and prostaglandin E2) in 
OA-affected cartilage,43 but is not thought to be involved in the 
adhesion of chondrocytes to cartilage44 or transmission for chon-
drocyte dedifferentiation.45 The αVβ3 integrin is also found in 
other joint tissues such as fi broblast-like synoviocytes.46
As cartilage loss and mild to moderate synovial infl ammation are 
recognised features of OA, especially at advanced stages (K&L3 and 
4) of the disease, the V65 vitronectin fragment could play an impor-
tant role in the pathogenesis of OA. Moreover, in the present study, 
OA progression is characterised by elevated serum levels of V65 
vitronectin fragments and CTX-II, and low serum levels of aggre-
can and pro-MMP-1, a typical pattern of progressive OA when the 
cell number declines,47 therefore the V65 vitronectin fragment may 
also be an important marker of disease outcome in OA.
The exact signifi cation of elevated levels of V65 vitronectin 
in OA remains unknown. Does it act as an agonist of αVβ3 
integrins or is it just a consequence of matrix degradation with 
deoxypyridinoline (dpd), and negatively correlated with kera-
tan sulphate epitope 5D4 (KS). Finally, CTAPIII was positively 
correlated with MMP-3, tumour necrosis factor α (TNFα) and 
aggrecan.
DISCUSSION
Using the SELDI-TOF-MS approach, four novel biomarkers for 
OA were detected, and all appeared to discriminate OA patients 
from control subjects (NC and RA), RA patients presenting a 
high DAS28 (>5.1). Two of the biomarkers have been identifi ed 
as the C-terminal end product of the V65 vitronectin subunit and 
C3f peptide. A third one at 3762 m/z value remains unidentifi ed 
due to its high hydrophobicity. These three biomarkers were 
found with increased levels of expression in sera of patients 
with severe OA and were also detected in synovial fl uids from 
the same patients. The fourth novel biomarker was identifi ed 
as a platelet-specifi c protein, CTAPIII, and was found to have a 
decreased level of expression in serum from patients with severe 
OA patients compared to patients with early stage disease.
V65 vitronectin fragment
The 1979 m/z peak identifi ed as a C-terminal end product of the 
V65 vitronectin subunit in the heparin binding domain, was pre-
dominantly detected in CM10 spectra of OA patients with the 
worst disease (K&L3 and 4) in Analysis and Validation studies. 
However, peak intensities were signifi cantly higher in all OA 
subsets, including K&L0, compared to control subjects (NC and 
RA) and further increased with increasing K&L scores. A prelim-
inary proteomics study on paired serum samples and synovial 
fl uids of OA patients revealed the presence of this fragment in 
Table 3 p Values illustrating peak intensities differences at m/z values 1979, 2021, 3762 and 9292 
between the four K&L subsets and compared to control subjects using data of Validation 1
Samples groups compared p Value – 1979 p Value – 2021 p Value – 3762 p Value – 9292
NC vs K&L0 0.0002 <0.0001 0.25 0.82
NC vs K&L1 0.0015 <0.0001 0.13 0.94
NC vs K&L2 <0.0001 <0.0001 0.02 0.33
NC vs K&L3 <0.0001 <0.0001 0.03 0.024
NC vs K&L4 <0.0001 <0.0001 0.004 0.020
NC vs K&L0 to 4 <0.0001 <0.0001 0.018 0.016
NC vs K&L1 to 4 <0.0001 <0.0001 0.012 0.011
RA vs K&L0 0.0005 <0.0001 0.53 0.27
RA vs K&L1 0.0021 <0.0001 0.41 0.61
RA vs K&L2 <0.0001 <0.0001 0.03 0.0516
RA vs K&L3 <0.0001 <0.0001 0.049 0.0006
RA vs K&L4 <0.0001 <0.0001 0.002 0.0274
RA vs K&L0 to 4 <0.0001 <0.0001 0.03 0.0071
RA vs K&L1 to 4 <0.0001 <0.0001 0.018 0.0041
K&L0 vs K&L1 0.89 0.88 0.99 0.76
K&L1 vs K&L2 0.21 0.65 0.22 0.14
K&L2 vs K&L3 0.32 0.07 0.97 0.1
K&L3 vs K&L4 0.12 0.02 0.11 0.43
K&L0 vs K&L2 0.09 0.53 0.11 0.37
K&L0 vs K&L3 0.006 0.43 0.22 0.013
K&L0,1 vs K&L2 to 4 0.0007 0.22 0.02 0.003
K&L0 to 2 vs K&L3,4 0.0012 0.0095 0.08 0.002
K&L1 vs K&L3 0.026 0.26 0.22 0.005
Statistically signifi cant comparisons are in bold.
NC, negative control subjects; RA, rheumatoid arthritis.
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However, CHCA was used instead of sinapinic acid (SPA) matrix 
in Validation 2 to better visualise small peptides below 2000 Da. 
Three peaks, at 1691, 1778 and 1865 m/z values were therefore 
detected with a high discriminatory power when comparing 
OA patients with the worst radiographic OA (K&L score 4) to 
patients with no radiographic OA (K&L score 0). These peaks 
were clustered on spectra and their m/z values correspond to 
truncated variants of C3f. C3f peptide is a fragment released 
during the catabolic degradation of C3b by Factor H after C3 
activation.50 C3f is further degraded to form C3f-des-Arg (pep-
tide mass of 1865 Da) and variants by carboxypeptidase N. A 
preliminary proteomics study on serum samples and synovial 
fl uids of OA patients revealed the presence of C3f peptides in 
both fl uids. Furthermore, C3f peptide serum levels were signifi -
cantly (and positively) correlated with V65 vitronectin serum 
levels in OA patients tested. Interestingly, vitronectin is also 
involved in the complement cascade, inhibiting the assembly 
extracellular matrix (ECM) protein release due to MMP activa-
tion? Indeed, it has been shown that vitronectin is a potential 
substrate of MMP family members, especially MMP-2, -3, -7 
and -9, suggesting that MMPs may participate in the turnover of 
vitronectin in tissues.48
C3f peptide and variants
The 2021 m/z peak identifi ed as C3f peptide was predominantly 
detected in IMAC-Ni2+ spectra from OA patients with the worst 
disease (K&L3 and 4) in both Analysis and Validation studies. 
Moreover, C3f peptide serum levels were signifi cantly higher in 
all OA subsets, including K&L0, compared to control subjects 
(NC and RA) and further increased with increasing K&L scores. 
A second validation study (Validation 2) was performed in a 
single day to circumvent false-positive biomarker detection due 
to extensive sample handling procedures as described by West-
Nørager et al,49 and was considered as a quality control study. 
Figure 3 Proteomic study on paired serum and synovial fl uid (SF) spectra provided from osteoarthritis (K&L1 to K&L4) and rheumatoid arthritis 
patients, illustrating presence or absence of peaks at m/z values of 1979 (A), 2021 (A and B), 1691 (B), 1778 (B), 1865 (B), 3762 (C) and 9292 (D) in 
both fl uids.
45_annrheumdis135541.indd   1150 4/26/2011   5:24:54 PM
 group.bmj.com on January 10, 2012 - Published by ard.bmj.comDownloaded from 
Extended report
Ann Rheum Dis 2011;70:1144–1152. doi:10.1136/ard.2010.135541 1151
of knee OA are characterised by low serum levels of CTAPIII, 
TNFα and MMP-3, also a typical pattern of progressive OA, 
when cell number declines.
CONCLUSION
The proteomic study detected four novel OA biomarkers. At 
least two, the V65 vitronectin fragment and C3f, can discrimi-
nate OA patients from healthy control subjects (NC) and disease 
control subjects (RA), and are therefore likely to be potential 
diagnostic markers for OA. V65 and C3f, as well as the remain-
ing unidentifi ed protein at m/z 3762, increased with increasing 
radiographic severity of OA and therefore are potential markers 
of disease stage. The levels of the fourth novel marker, CTAPIII 
protein, were lower in more severe stages of OA (K&L grades 3 
and 4) but higher in both sets of control subjects, and were cor-
related to markers of infl ammation suggesting that this marker 
might refl ect a proinfl ammatory pathway. The proteomics study 
reported here is based on samples obtained from a cross-sec-
tional prospective study, the limitations of which are described 
in the supplementary data.
There is a need for further studies using serum samples from 
new cohorts, a wider range of disease control subjects, as well as 
longitudinal studies to establish the usefulness of the four novel 
biomarkers identifi ed.
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